(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 25.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Vericel's revenue in 2025 is $238,541,000.On average, 3 Wall Street analysts forecast VCEL's revenue for 2025 to be $14,425,576,395, with the lowest VCEL revenue forecast at $14,354,794,181, and the highest VCEL revenue forecast at $14,508,340,236. On average, 3 Wall Street analysts forecast VCEL's revenue for 2026 to be $18,650,710,754, with the lowest VCEL revenue forecast at $17,575,737,337, and the highest VCEL revenue forecast at $19,593,986,964.
In 2027, VCEL is forecast to generate $24,211,192,366 in revenue, with the lowest revenue forecast at $23,718,586,415 and the highest revenue forecast at $24,703,798,318.